

## Helix BioMedix Announces Upcoming Scientific Presentations

May 18, 2004 - Bothell, Washington

Helix BioMedix, Inc. (OTC Bulletin Board: [HXBM.OB](#) - News) today announced that it will be presenting at the 14th Annual Wound Healing Society Meeting in Atlanta, GA (May 23-26, 2004) and the 104th AGM of the American Society for Microbiology in New Orleans, LA (May 23-27, 2004).

*"Those following Helix BioMedix know that we are actively working with potential licensees for our technology," stated Stephen Beatty, President and CEO. "Included with this undertaking is the continuing role played by our scientists. Through their professional papers and appearances, they enhance our standing in the scientific community and facilitate our business development initiatives. I am pleased to announce our upcoming presentations."*

On May 23rd and 25th, Dr. Scott Harris, Director of Chemistry, will present research findings relating to the prevention of wound infection using a topical anti-microbial peptide and the stimulation of wound healing by topically applied peptides at the Annual Wound Healing Society Meeting at the Sheraton Atlanta Hotel. On May 24th from 1 to 4 p.m. in the Poster Hall, Dr. Lijuan Zhang, Principal Scientist, will present results on the prevention of sexually transmitted diseases by topically applied peptides at the Ernest N. Morial Convention Center in New Orleans. Dr Zhang's presentation will also be highlighted in the conference press room.

Additionally, the company announced that its initial in vivo work on its pre-clinical wound healing lead candidate, HB107, is to be published in the May 2004 issue of The Journal of Wound Healing and Regeneration.

*"These presentations and publications are testament to the Company's ongoing commitment to high quality scientific research," stated Timothy Falla, Chief Scientific Officer. "Combined with invited reviews of the field, such as 'Cationic antimicrobial peptides -- an update' in January's edition of Expert Opinion in Investigational Drugs, these presentations highlight Helix BioMedix's well respected standing in the field of bioactive peptide research and development."*

### About Helix BioMedix:

Helix BioMedix, Inc. is an early-stage biotechnology company that has a portfolio of issued patents which covers six distinct classes of peptides, covering over 100,000 unique peptide sequences. The company's mission is to become the industry leader in developing and commercializing small proteins known as bioactive peptides. The antimicrobial and wound healing properties of these peptides qualify them for inclusion in a wide range of both pharmaceutical and consumer products. The company is currently focused on the development of selected peptides as topical anti-infectives and in wound healing. Non-pharmaceutical applications being pursued by Helix BioMedix include adjuvants for cosmetics/cosmeceuticals, personal care, plant health, animal health and wide-spectrum biocides. More information about the company and its proprietary peptides can be found on the company's website at [www.helixbiomedix.com](http://www.helixbiomedix.com).